The data from the trial were published today in the New England Journal of Medicine. Triple-negative breast cancer is an aggressive disease and is more common, relative to other breast cancers, in young women and African-American women. Triple-negative breast cancers do not express the estrogen receptor, progesterone receptor, or HER2. Thus, historically, treatments only included chemotherapy for triple-negative breast cancer and not targeted therapy, such as hormone therapy or Herceptin. The drug, sacituzumab govitecan, is part of an emerging class of "smart drugs" designed to deliver a toxic payload directly to tumor cells. The drug is a fusion of an antibody that recognizes a protein expressed by breast cancer cells known as trop2 and the metabolite of an established chemotherapy drug irinotecan , SN
5 Of The Biggest Breast Cancer Breakthroughs Of 2016
New breast cancer treatment offers hope of longer life to younger women | Society | The Guardian
December 18, Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team of FSU researchers is now a little bit closer to figuring out why. Associate Professor of Statistics Jinfeng Zhang, Professor of Chemistry and Biochemistry Qing-Xiang "Amy" Sang, and graduate students Mayassa Burjas Bou Dargham and Yuhang Liu analyzed data from more than 1, breast cancer patients and found that breast cancer behaves differently than other cancers that are currently treated with immunotherapy. Immunotherapy is a course of treatment where drugs unleash the body's own immune system to fight cancer. When cancer invades the body, the immune system often fails to recognize it as abnormal. Immunotherapy drugs inactivate the mechanisms cancer cells have that allow them to hide from the immune system.
Breakthroughs in Breast Cancer Research
A team of experts centered on your treatment, caring for the whole person. Offering clinical trials on new and emerging cancer treatment options. Our hospitals and Outpatient Care Centers accept a wide range of insurance plans. After skin cancer , breast cancer is the second most commonly diagnosed cancer among U. The disease forms when breast cells mutate change and multiply uncontrollably, forming a tumor.
We round up some of the latest developments in treatments for people with secondary breast cancer. Our ambition as a charity is to stop breast cancer deaths, and this can only be achieved by improving treatments for secondary breast cancer. Last year saw results released from several clinical trials which are finding better ways to keep secondary breast cancer under control. In this blog we summarise the highlights from clinical trials in , grouped by the type of breast cancer.